{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:23:57Z","timestamp":1792567437233,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00198-024-07351-7","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T12:56:50Z","timestamp":1736341010000},"page":"435-446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical experience with denosumab discontinuation"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6740-3072","authenticated-orcid":false,"given":"Natasha","family":"Laursen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"S\u00f8lling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Harsl\u00f8f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"issue":"7","key":"7351_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5(7):513\u201323","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"7351_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 361(8):756\u201365","journal-title":"N Engl J Med."},{"issue":"4","key":"7351_CR3","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 96(4):972\u201380","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"7351_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M et al (2018) Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 33(2):190\u20138","journal-title":"J Bone Miner Res."},{"issue":"4","key":"7351_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","volume":"101","author":"IR Reid","year":"2017","unstructured":"Reid IR, Horne AM, Mihov B, Gamble GD (2017) Bone Loss After Denosumab: Only Partial Protection with Zoledronate. Calcif Tissue Int. 101(4):371\u20134","journal-title":"Calcif Tissue Int."},{"issue":"Suppl 2","key":"7351_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/annrheumdis-2019-eular.4175","volume":"78","author":"B Aubry-Rozier","year":"2019","unstructured":"Aubry-Rozier B, Liebich G, Stoll D, Gonzalez-Rodriguez E, Hans D, Lamy O (2019) Can we avoid the loss of bone mineral density one year after denosumab discontinuation? The Reolaus Bone Project. Annals of the Rheumatic Diseases. 78(Suppl 2):115","journal-title":"Annals of the Rheumatic Diseases."},{"issue":"7","key":"7351_CR7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","volume":"35","author":"J Everts-Graber","year":"2020","unstructured":"Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T (2020) A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Miner Res. 35(7):1207\u201315","journal-title":"J Bone Miner Res."},{"issue":"10","key":"7351_CR8","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS S\u00f8lling","year":"2020","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res. 35(10):1858\u201370","journal-title":"J Bone Miner Res."},{"issue":"7","key":"7351_CR9","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS S\u00f8lling","year":"2021","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res. 36(7):1245\u201354","journal-title":"J Bone Miner Res."},{"key":"7351_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 106:264\u2013281","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"7351_CR11","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 28(5):1723\u201332","journal-title":"Osteoporos Int."},{"key":"7351_CR12","doi-asserted-by":"publisher","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","volume":"109","author":"G Grassi","year":"2024","unstructured":"Grassi G, Ghielmetti A, Zampogna M, Chiodini I, Arosio M, Mantovani G et al (2024) Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion? J Clin Endocrinol Metab 109:e1817\u2013e1826","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"7351_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","volume":"103","author":"AW Popp","year":"2018","unstructured":"Popp AW, Varathan N, Buffat H, Senn C, Perrelet R, Lippuner K (2018) Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis. Calcif Tissue Int. 103(1):50\u20134","journal-title":"Calcif Tissue Int."},{"issue":"10","key":"7351_CR14","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","volume":"106","author":"P Makras","year":"2021","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA et al (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab. 106(10):e4155\u2013e62","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"7351_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","volume":"29","author":"MB Zanchetta","year":"2018","unstructured":"Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR (2018) Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos Int. 29(1):41\u20137","journal-title":"Osteoporos Int."},{"issue":"2","key":"7351_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00198-022-06610-9","volume":"34","author":"AS S\u00f8lling","year":"2023","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Brockstedt HK, Langdahl B (2023) Discontinuation of denosumab in men with prostate cancer. Osteoporos Int. 34(2):291\u20137","journal-title":"Osteoporos Int."},{"issue":"9","key":"7351_CR17","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 95(9):4380\u20137","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"7351_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jbmr.4434","volume":"37","author":"DM Black","year":"2022","unstructured":"Black DM, Reid IR, Napoli N, Ewing SK, Shiraki M, Nakamura T et al (2022) The interaction of acute-phase reaction and efficacy for osteoporosis after zoledronic acid: HORIZON pivotal fracture trial. J Bone Miner Res. 37(1):21\u20138","journal-title":"J Bone Miner Res."},{"issue":"2","key":"7351_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","volume":"23","author":"JD Wark","year":"2012","unstructured":"Wark JD, Bensen W, Recknor C, Ryabitseva O, Chiodo J 3rd, Mesenbrink P et al (2012) Treatment with acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int. 23(2):503\u201312","journal-title":"Osteoporos Int."},{"issue":"5","key":"7351_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/jbmr.4802","volume":"38","author":"R Murdoch","year":"2023","unstructured":"Murdoch R, Mellar A, Horne AM, Billington E, Chan PL, Gamble GD et al (2023) Effect of a three-day course of dexamethasone on acute phase response following treatment with zoledronate: a randomized controlled trial. J Bone Miner Res. 38(5):631\u20138","journal-title":"J Bone Miner Res."},{"issue":"6","key":"7351_CR21","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 32(6):1291\u20136","journal-title":"J Bone Miner Res."},{"key":"7351_CR22","unstructured":"Department of Encrinology and Internal Medicine AUHD. Treatment with zoledronate subsequent to denosumab in osteoporosis 2 (ZOLARMAB2) 2023 [cited 2024. NCT05655013]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05655013?term=zolarmab2&checkSpell=&rank=1"},{"issue":"3","key":"7351_CR23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s12020-022-03230-5","volume":"80","author":"AA Khan","year":"2023","unstructured":"Khan AA, AbuAlrob H, M\u2019Hiri I, Ali DS, Dandurand K, Said H et al (2023) Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study. Endocrine. 80(3):647\u201357","journal-title":"Endocrine."},{"issue":"7","key":"7351_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10731","volume":"7","author":"M Laroche","year":"2023","unstructured":"Laroche M, Couture G, Degbo\u00e9 Y (2023) Discontinuation of denosumab: gradual decrease in doses preserves half of the bone mineral density gain at the lumbar spine. JBMR Plus. 7(7):e10731","journal-title":"JBMR Plus."},{"issue":"1","key":"7351_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S et al (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 23(1):317\u201326","journal-title":"Osteoporos Int."},{"issue":"5","key":"7351_CR26","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00198-018-04820-8","volume":"30","author":"O Lamy","year":"2019","unstructured":"Lamy O, Fern\u00e1ndez-Fern\u00e1ndez E, Monjo-Henry I, Stoll D, Aubry-Rozier B, Benavent-N\u00fa\u00f1ez D et al (2019) Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports. Osteoporos Int. 30(5):1111\u20135","journal-title":"Osteoporos Int."}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07351-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-024-07351-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07351-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T09:31:03Z","timestamp":1741167063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-024-07351-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["7351"],"URL":"https:\/\/doi.org\/10.1007\/s00198-024-07351-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ASS has received lecture fees from Amgen. TH has received speaker fees from UCB, Amgen, AstraZeneca and Astellas Pharma. BL has received lectures fees from Amgen and serves as a consultant for UCB, Mereo and Samsung-Bioepis. NL declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}